GlassScriptPhysician profile
Nicholas A Klaiber
NPI 1396182275
$46,171.52
in general payments reported to CMS, 2019-2025
34 companies · $12K in 2025
The $12K reported for 2025 was more than what 89% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,179 · 2020: $710 · 2021: $1,164 · 2022: $2,868 · 2023: $7,174 · 2024: $21K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Food and Beverage: $5,933 · Consulting Fee: $4,960 · Travel and Lodging: $1,705 · Education: $128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,525.00 |
| Food and Beverage | $5,932.86 |
| Consulting Fee | $4,960.00 |
| Travel and Lodging | $1,705.10 |
| Education | $127.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $32,314.14 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Genentech USA, INC. | $6,169.01 | 2021-2025 | Xolair |
| Glaxosmithkline, LLC. | $1,553.80 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,265.74 | 2019-2025 | Dupixent |
| Genzyme Corporation | $704.55 | 2019-2025 | |
| Pfizer INC. | $619.72 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $528.43 | 2020-2025 | Takhzyro, Cuvitru, Hyqvia |
| Novartis Pharmaceuticals Corporation | $474.24 | 2019-2025 | |
| Greer Laboratories, INC. | $311.73 | 2024-2025 | Palforzia, Oralair |
| Grifols USA, LLC | $293.58 | 2019-2025 | Xembify |
| Amgen INC. | $289.04 | 2021-2025 | Tezspire |
| Kaleo, INC. | $203.65 | 2019-2024 | Auvi-Q |
| Optinose US, INC. | $201.31 | 2019-2021 | |
| Biocryst US Sales Co., LLC | $189.72 | 2021-2025 | Orladeyo |
| Pharming Healthcare, INC. | $129.29 | 2022-2025 | Ruconest |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $114.20 | 2023-2025 | Ayvakit |
| Csl Behring | $108.65 | 2019 | |
| Lilly USA, LLC | $85.71 | 2024-2025 | Ebglyss, Taltz |
| Incyte Corporation | $80.01 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $68.58 | 2022-2023 | Adbry |
| Shire North American Group INC | $64.53 | 2019 | |
| Aimmune Therapeutics, INC. | $60.48 | 2021-2022 | |
| Hikma Pharmaceuticals USA | $52.69 | 2023-2024 | Ryaltris |
| Alk-Abello, INC | $44.76 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.36 | 2020-2021 | |
| Ars Pharmaceuticals Operations, INC. | $32.61 | 2025 | Neffy |
| Galderma Laboratories, L.P. | $30.42 | 2025 | Nemluvio |
| Teva Pharmaceuticals USA, INC. | $25.00 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $23.83 | 2019 | |
| Cycle Pharmaceuticals INC | $20.36 | 2025 | Sajazir |
| Merck Sharp & Dohme LLC | $19.55 | 2023 | |
| Phadia US INC. | $17.94 | 2022 | |
| Circassia INC. | $15.69 | 2019 | |
| Eyevance Pharmaceuticals LLC | $14.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Klaiber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.